Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Neoplasms 9Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Breast Neoplasms 5Adenocarcinoma 5Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Renal Cell 4Urethral Neoplasms 3Rectal Neoplasms 3Liver Neoplasms 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Malignant Solid Tumor 2Carcinoma, Transitional Cell 2Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Gemcitabine 34Cisplatin 21Capecitabine 18Oxaliplatin 15Leucovorin 10Fluorouracil 10Irinotecan 8Erlotinib Hydrochloride 7pembrolizumab 5Bevacizumab 5Radiotherapy 4Carboplatin 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Watchful Waiting 3Taxes 3Sorafenib 3Platinum 3Interleukin-12 Subunit p35 3Immunohistochemistry 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3trifluridine tipiracil drug combination 2tremelimumab 2regorafenib 2durvalumab 2dehydroftorafur 2Trastuzumab 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gallbladder Neoplasms × Ramucirumab × Clear all
NCT02520141 2023-06-15

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Completed
61 enrolled 9 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡